Galmed Pharmaceuticals Ltd. EOCN
Galmed Pharmaceuticals Ltd. (Nasdaq: EOCN) is an oncology drug developer. Its lead program, Aramchol, is in Phase 2 for Oncology (GI cancers, development being advanced); historically NASH/MASH and fibrosis. Its next catalyst on record is CG-100 (Colospan): Submit real-world data to FDA to support US pivotal study; first device revenue (2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: CG-100 (Colospan) — Submit real-world data to FDA to support US pivotal study; first device revenue (2026). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Aramchol ARMOR Phase 3 (NASH/fibrosis) - open-label part discontinued 2022; second part not expected to start | NASH/MASH with fibrosis | small molecule | Phase 3 |
| Aramchol (oncology indications; no active trial described) | GI oncology indications outside NASH | small molecule | Phase 2 |
| CG-100 intraluminal bypass device (Colospan; CE marked, US pivotal IDE study ongoing) | Protection of colorectal anastomoses / avoiding diverting stoma | device-combination | NA_NON_THERAPEUTIC |
| Intraoperative colon tissue assessment platform (Colospan) | Colorectal surgery tissue quality | unclear | NA_NON_THERAPEUTIC |
Recent results and decisions
- Aug 19, 2026positive Single-arm feasibility study in 32 colorectal cancer patients: colon tissue compliance measured successfully in all 32 with no measurement failures.
Successful measurements obtained in all 32 patients with no measurement failures or procedure-related technical issues.
Filing - Nov 18, 2025positive Phase 1 AM-001 in 30 healthy volunteers: Aramchol meglumine 400mg and 200mg granules had about 5-fold and 3-fold the bioavailability of Aramchol free acid 300mg tablets, supporting once-daily dosing.
The BA of 400mg and 200mg Aramchol meglumine granules were approximately 5-fold and 3-fold respectively, from that of the Aramchol free acid 300 mg tablets.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.